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Abstract  
Recent hospital-based cohort studies found the CHA2DS2-VASc score to be associated with 
ischemic stroke in individuals without atrial fibrillation (AF). Our aim was to determine the 
distribution of embolic and thrombotic strokes and association with the CHA2DS2-VASc 
score, among community-dwelling individuals without AF. We included participants from 
the Atherosclerosis Risk in Communities (ARIC) Study who attended visit 4 (1996-98) and 
had no prior AF, stroke, or anticoagulant use (n=10,671).  During follow-up through 2008, 
incident AF cases (n=760) and participants who started warfarin were censored. Incident AF 
was ascertained from study ECGs and hospital discharge diagnosis codes, and stroke was 
physician-adjudicated. After 10 years of follow-up, 280 ischemic strokes were identified, of 
which 146 were thrombotic and 57 embolic. The hazard ratios (95% confidence intervals 
[CI]) for thrombotic stroke were 1 (reference), 1.71 (1.13-2.59), 2.92 (1.91-4.45), 3.22 (1.70-
6.11), and 1.25 (0.17-9.09), with CHA2DS2-VASc scores of 0-1, 2, 3, 4, and 5, respectively. 
The hazard ratios (95% CI) for embolic stroke were 1 (ref), 4.91 (2.10-11.5), 7.07 (2.93-
17.0), 14.8 (5.50-39.6), and 15.2 (3.16-73.3), with CHA2DS2-VASc scores of 0-1, 2, 3, 4, and 
5, respectively. A receiver-operating characteristic model had a C statistic of 0.65 for 
ischemic stroke, 0.61 for thrombotic stroke, and 0.71 for embolic stroke. In conclusion, in 
community-dwelling individuals without AF, the CHA2DS2-VASc score can assess ischemic 
stroke risk and has good discriminatory capacity for embolic stroke.  
 
Key words: Ischemic stroke; CHA2DS2-VASc score; Epidemiology 
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Introduction 
The CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 years [doubled], 
diabetes, stroke/transient ischemic attack/thromboembolism [doubled], vascular disease, age 
65-74 years, female sex is widely used to stratify the risk of ischemic stroke in nonvalvular 
atrial fibrillation (AF).
1
 Recent evidence suggests that the CHA2DS2-VASc score may also 
predict ischemic stroke in individuals without AF.
2–6
 These studies, however, were comprised 
of highly-selected individuals, often lacked adjudication of stroke, and did not account for the 
competing risk of death. Furthermore, the proportion of thrombotic versus embolic strokes 
were not reported, which could clarify the role for anticoagulation in those without AF. We 
therefore aimed to evaluate the association of the CHA2DS2-VASc score with incident 
ischemic stroke—paying particular attention to the association with thrombotic and embolic 
subtypes—among community-dwelling individuals without AF from the Atherosclerosis 
Risk in Communities (ARIC) study. 
 
Methods 
The ARIC study is a prospective community-based cohort study that was designed to 
investigate the causes of atherosclerosis and its clinical outcomes as well as variation in 
cardiovascular risk factors, medical care, and disease by race and sex.
7
 From 1987 to 1989 
(ARIC study baseline), 15,792 adults (55% women, 45-64 years of age) from 4 US 
communities (Washington County, MD; suburbs of Minneapolis, MN; Jackson, MS; and 
Forsyth County, NC) were enrolled and underwent a home interview and clinic visit. After 
the visit 1 examination, there were 4 additional exams: visit 2 (1990−1992), visit 3 
(1993−1995), visit 4 (1996−1998) and visit 5 (2011-2013). Refer to Supplemental Material 
for further details.  
We included all ARIC participants who attended visit 4 (n = 11,656) (1996-1998). 
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4 
Visit 4 was used as the baseline because patients were now older and had more 
cardiovascular risk factors, yielding a wider spread of CHA2DS2-VASc scores which 
facilitated our analyses. Of the visit 4 attendees, we excluded those with prevalent AF or 
unreadable ECG (n= 524), prevalent stroke (n = 360), and prior anticoagulant use (n=101). 
After these exclusions, there were 10,671 participants for the main analysis.  Participants 
were censored if they developed AF or began anticoagulant therapy during the follow-up 
period, regardless of the indication. Figure 1 illustrates the flow of study participants.  
AF cases were identified from review of hospital discharge diagnoses.
8,9
 AF during 
follow-up was defined as International Classification of Disease 9th revision, Clinical 
Modification [ICD-9-CM] 427.31 or 427.32 diagnosis codes. Hospital diagnosis codes for 
AF ascertainment have been shown to have good positive predictive value of 98.6%.
8,10
  
Stroke at visit 1 was defined as a self-reported history of physician-diagnosed stroke, 
while stroke after visit 1 was adjudicated.
11
 To identify subsequent stroke, cohort participants 
were followed over time through annual telephone interviews, field center examinations, 
surveillance of the ARIC community hospitals for all cohort members’ hospitalizations, and 
the review of death certificates, physician questionnaires, coroner/medical examiner reports, 
and informant interviews. The Supplemental Material explains how hospitalizations for 
possible validation of stroke were identified. Once identified, pertinent medical records from 
hospitalizations were copied and sent to a single nurse abstractor at a central ARIC office 
who abstracted each record for pertinent information (see Supplemental Material). Next, 
using criteria adopted from the National Survey of Stroke,
12
 strokes were classified by 
computer algorithm and categorized into 1 of 4 main types: SAH, intracerebral hemorrhage, 
thrombotic brain infarction, or embolic brain infarction (with carotid and non-carotid 
subtypes) (see Supplemental Material for computerized algorithm). In addition to a 
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computer-determined diagnosis, cases were independently reviewed by a physician, who was 
provided with all pertinent details from the medical records. Disagreement between the 
computer and physician classification were adjudicated by a second physician-reviewer. 
Aside from a classification algorithm (see Supplemental Material), physicians also used 
their own discretion when the clinical picture deviated from the algorithm. Only “definite” 
but not “probable” ischemic strokes were further classified into thrombotic or embolic 
subtypes. 
For this analysis, covariates included all CHA2DS2-VASc score components. 
Covariates were taken from visit 4. Definitions of the covariates are detailed in the 
Supplemental Material.   
In our analysis, the crude 10-year incidence of stroke was calculated for each 
predictor and CHA2DS2-VASc score category. Hazard ratios to assess the association 
between each variable and stroke were calculated using univariate Cox proportional hazards 
models. To account for competing risk of death, 1-, 5-, and 10-year absolute risks for 
ischemic stroke stratified by CHA2DS2-VASc categories in participants using the Aalen-
Johansen estimator (see Supplemental Material for more information).  
Results 
 Of the 10,671 participants (mean age 62.7 years; 57% women; 23% non-whites) 
included in this 10-year analysis, 280 (2.6%) developed ischemic stroke. The mean follow-up 
was 9.3±1.9 years. Baseline clinical characteristics of the study are shown in Table 1, 
stratified by ischemic stroke. Participants who developed ischemic stroke were older and 
more likely to be non-white, non-female, and on aspirin compared to those who did not 
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6 
develop ischemic stroke. Additionally, participants who developed ischemic stroke had a 
higher prevalence of each variable of the CHA2DS2-VASc score (except female status). 
Table 2 shows the crude 10-year incidence and hazards ratios for ischemic stroke, and 
thrombotic and embolic subtypes, for each CHA2DS2-VASc score category and individual 
component. With increasing CHA2DS2-VASc score, the 10-year incidence of ischemic stroke 
increased from 1.3 per 1000 person-years (score 0-1) to 8.9 per 1000 person-years (score ≥ 
5). Similarly, the incidence for both thrombotic (except for score ≥ 5) and embolic subtypes 
increased with increasing CHA2DS2-VASc score. With increasing CHA2DS2-VASc score, 
the hazard ratios for ischemic stroke, thrombotic subtype (except for score ≥ 5), and embolic 
subtype also increased, although in a more exponential manner for embolic subtype 
compared to thrombotic subtype (more linearly).  Univariate predictors for ischemic stroke 
included age 65 to 74, male sex, heart failure, hypertension, diabetes, vascular disease, and 
aspirin use; univariate predictors of thrombotic stroke included age 65 to 74, male sex, 
hypertension, diabetes, and vascular disease. Univariate predictors for embolic stroke 
included age 65 to 74, heart failure, hypertension, and diabetes. 
Figure 2 shows that the CHA2DS2-VASc score provided moderate discriminatory 
performance for ischemic and thrombotic stroke, but good discriminatory performance for 
embolic stroke. The C-statistic (95% CI) was 0.65 (0.62-0.68) for ischemic stroke, 0.61 
(0.56-0.65) for thrombotic stroke, and 0.71 (0.65-0.77) for embolic stroke. 
Table 3 combines the 1- and 5-year crude incidences of ischemic stroke with the 10-
year results. Similar to the 10-year follow up, there was an increasing risk in 1- and 5-year 
ischemic stroke with increasing CHA2DS2-VASc scores. Thrombotic and embolic subtypes 
were not calculated at 1 or 5 years due to relatively low event rates.  
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7 
Sensitivity analyses were performed to assess the impact of aspirin and anticoagulant 
use on these results. Not excluding participants on anticoagulation at baseline or during 
follow up had a miniscule effect on the results (Supplemental Table I) as was also the case 
after adjusting the main analysis for aspirin (Supplemental Table II).  
Taking into account the competing risk of death, the 1-year absolute risk of ischemic 
stroke was 0.1%, 0.4%, 0.3%, and 1.2%, and 3.5% for CHA2DS2-VASc scores of 0-1, 2, 3, 4 
and 5, respectively. Absolute stroke risks at 5 years were 0.6%, 1.8%, 2.1%, 3%, and 5.2% 
for CHA2DS2-VASc scores 0-1, 2, 3, 4, and ≥5, respectively. Absolute stroke risks at 10 
years were 1.2%, 3.1%, 4.6%, 5.8%, and 7%, for CHA2DS2-VASc scores 0-1, 2, 3, 4, and ≥5, 
respectively (Figure 3). 
Discussion 
In this large cohort of middle-aged, community-dwelling individuals without AF, 
higher CHA2DS2-VASc scores were associated with higher risk of ischemic stroke, including 
both thrombotic and embolic subtypes. The embolic stroke risk, while low in participants 
with a CHA2DS2-VASc scores of 0-1, increased exponentially in the setting of cumulative 
risk factors, carrying a 5-fold greater risk at a score of 2 and a 15-fold greater risk at a score 
of 4. The risk of thrombotic stroke also increased with higher CHA2DS2-VASc score but 
more linearly than in embolic stroke. This suggests that, when combined, the risk factors of 
the CHA2DS2-VASc score have a potentiating effect that markedly increases embolic stroke 
risk. In addition, the CHA2DS2-VASc score demonstrated good discriminatory performance 
in the prediction of embolic stroke, and modest performances for ischemic and thrombotic 
stroke.  The findings of this study suggest that the CHA2DS2-VASc score may be useful as a 
prediction tool for ischemic stroke, including embolic stroke, in people without AF.  
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For patients with AF, current guidelines recommend anticoagulation for a CHA2DS2-
VASc of 2 (and higher), which confers a 2.2% per year stroke risk, although anticoagulation 
can be considered for a score of 1, which confers a 1.3% per year stroke risk.
13
 In our present 
study of non-AF individuals, after accounting for the competing risk of death, the 1-year 
absolute risks of ischemic stroke were 1.2% and 3.5% for CHA2DS2-VASc scores of 4 and ≥ 
5, respectively. Further, we have demonstrated that embolic stroke risk—in which 
anticoagulation would be particularly useful—increases exponentially in non-AF participants 
with increasing CHA2DS2-VASc scores. Collectively, these findings suggest that 
antithrombotic therapy may be useful at a CHA2DS2-VASc score of ≥ 5 in non-AF patients, 
although further studies evaluating their effect would be needed. 
The mechanisms by which CHA2DS2-VASc risk factors contribute to the 
pathogenesis of thromboembolism in AF are not well understood. Conventional wisdom 
holds that in the absence of the dysrhythmia of AF, these vascular risk factors per se do not 
increase the risk of thromboembolism; AF is often presumed to be a necessary instigating 
factor for thromboembolism.  In our study, however, the association between increasing 
CHA2DS2-VASc score and increasing risk of embolic stroke was observed in the absence of 
AF. This observation suggests that these risk factors, in and of themselves, may be 
intrinsically pro-thrombotic.  This is supported by studies showing that maintenance of sinus 
rhythm versus a rate-control strategy does not reduce the risk of stroke.
14
 Also, studies 
assessing subclinical AF in patients with implanted cardiac devices (e.g. pacemakers and 
defibrillators) have shown an increased risk of stroke with higher AF burden, but have failed 
to show a temporal relationship between the timing of AF events and stroke.
15,16
 Studies have 
also shown paroxysmal supraventricular tachycardias to be associated with stroke, although 
the mechanism and causality of this relationship remains unclear.
17
 Finally, ECG-defined left 
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9 
atrial abnormalities and left atrial enlargement have been shown to be associated with 
ischemic stroke, independent of AF.
11,18,19
  
The principal strengths of our study include a prospective community-based investigation 
with meticulous physician-adjudication of ischemic stroke, including classification of 
thrombotic and embolic stroke. Other strengths include inclusion of community non-white 
participants, extensive measurement of covariates, and large number of participants. Several 
limitations need to be considered. First, the higher CHA2DS2-VASc categories had a small 
number of events, and thus were combined. Second, it is possible that non-hospitalized stroke 
events that were not validated in the study could influence the results, although 
underestimation of the rate of stroke is estimated to be small (<5%).
20
 Third, we recognize 
that the criteria for classifying embolic stroke were not as rigorous compared to those 
currently recommended, and the classification for cryptogenic stroke was not used in the 
study.
21
 Fourth, adjustment for aspirin did not affect our results, which was unexpected in 
that it should have been associated with fewer thrombotic strokes. Finally, AF was identified 
mostly from hospitalization discharges in ARIC and we could not include asymptomatic AF 
or AF managed exclusively in an outpatient setting. However, prior analysis within the ARIC 
cohort to determine the validity of hospital discharge diagnoses for AF reported 84% 
sensitivity and 98% specificity in AF ascertainment,
9
 and that incidence rates of AF in ARIC 
are consistent with other population-based studies.
22–24
 
In conclusion, the CHA2DS2-VASc score may be used to assess the risk of ischemic 
stroke, including both thrombotic and embolic subtypes, in community-dwelling people 
without AF. Our findings will need to be replicated in other cohorts. If replicated, further 
research would be needed to determine whether anticoagulant use in certain individuals 
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without AF but with high CHA2DS2-VASc risk scores would reduce the risk of ischemic 
stroke. 
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Figure Legends 
 
Figure 1. Participant selection flowchart.    
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Figure 2. Receiver operating characteristic curves for the CHA2DS2-VASc scores for 
prediction of ischemic stroke, thrombotic stroke, and embolic stroke in participants without 
atrial fibrillation. 
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Figure 3. Absolute ischemic stroke risks by CHA2DS2-VASc risk score during 1-, 5-, and 
10- years of follow-up, accounting for competing risk of death.
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Table 1. Baseline Characteristics of Participants without Atrial Fibrillation† in the Atherosclerosis Risk in Communities 
(ARIC) Study at Visit 4 (1996-98), stratified by future ischemic stroke  
 
No AF  
(n= 10,671) 
Ischemic stroke (within 10 
years) (n=280) 
No stroke (within 10 years) 
(n=10,391) 
Mean age (SD), years 62.7 (5.6) 65.1 (5.6) 62.6 (5.6) 
Non-white race  2435 (23%) 99 (35%) 2336 (22%) 
Female 6039 (57%) 134 (48%) 5905 (57%) 
Hypertension 4936 (46%) 187 (67%) 4749 (46%) 
Hyperlipidemia 5897 (55%) 158 (56%) 57339 (55%) 
Diabetes mellitus 1699 (16%) 89 (32%) 1610 (15%) 
Heart failure 470 (4%) 24 (9%) 446 (4%) 
Peripheral arterial disease / MI 861 (8%) 49 (18%) 812 (8%) 
Coronary heart disease 788 (7%) 26 (16%) 742 (7%) 
CHA2DS2VASc score 1.7 (1.1) 2.3 (1.1) 1.7 (1.1) 
Aspirin use 5968 (56%) 184 (66%) 5784 (56%) 
Statin use 1168 (11%) 35 (13%) 1133 (11%) 
AF is for atrial fibrillation; MI, myocardial infarction 
† Also excluding anticoagulant use at baseline (n=101) 
Medication history was obtained by self-report of medication intake during the prior 2 weeks before Visit 4 and by reviewing 
medications brought by the participants to the Visit 
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† Excluding and censoring anticoagulant use at baseline and follow up  
‡ Incidence rates for thrombotic and embolic stroke includes “definite” stroke only; ischemic stroke incidence includes “definite” as 
well as “probable” stroke.  
§ Insufficient data (only 1 patient was aged ≥75 at baseline) 
  
Table 2.  Univariate analysis and incidence rates per 1,000 person-years for ischemic stroke, thrombotic stroke, and embolic stroke in 
participants without atrial fibrillation,
†
 Atherosclerosis Risk in Communities Study, (1996-2005) 
 Ischemic stroke Thrombotic stroke‡ Embolic stroke‡ 
Events within 10 yrs 280 146 57 
Incidence rates 2.8 1.5 0.58 
Individual predictors Incidence HR (95% CI) Incidence  HR (95% CI) Incidence  HR (95% CI) 
Age ≥75§ -- -- -- -- -- -- 
Age 65-74 vs. <65 4.3 2.22 (1.75-2.81) 2.1 1.89 (1.37-2.62) 1.0 3.13 (1.82-5.39) 
Male vs. female sex 3.5 1.48 (1.17-1.87) 1.8 1.52 (1.10-2.11) 0.55 0.92 (0.54-1.56) 
Heart failure 6.2 2.29 (1.51-3.48) 1.8 1.24 (0.58-2.65) 2.3 4.59 (2.25-9.36) 
Hypertension 4.2 2.42 (1.89-3.11) 1.9 1.78 (1.28-2.48) 0.91 3.09 (1.73-5.51) 
Hyperlipidemia 2.9 1.04 (0.82-1.32) 1.6 1.15 (0.83-1.60) 0.44 0.61 (0.37-1.03) 
Diabetes mellitus 6.0 2.64 (2.05-3.40) 3.2 2.71 (1.91-3.83) 1.2 2.62 (1.50-4.59) 
Vascular disease 6.7 2.68 (1.97-3.65) 2.7 2.02 (1.26-3.24) 1.1 2.07 (0.98-4.37) 
Aspirin 3.3 1.54 (1.20-1.97) 1.6 1.29 (0.93-1.80) 0.63 1.28 (0.75-2.18) 
Statin use 3.3 1.18 (0.83-1.69) 1.7 1.17 (0.71-1.91) 0.37 0.61 (0.22-1.69) 
CHA2DS2-VASc       
  0-1 reference 1.3 1 (ref) 0.91 1 (ref) 0.15 1 (ref) 
  2 3.3 2.54 (1.85-3.49) 1.6 1.71 (1.13-2.59) 0.72 4.91 (2.10-11.5) 
  3 5.0 3.80 (2.73-5.28) 2.6 2.92 (1.91-4.45) 1.0 7.07 (2.93-17.0) 
  4 6.8 5.16 (3.30-8.06) 2.9 3.22 (1.70-6.11) 2.2 14.8 (5.50-39.6) 
  ≥5 8.9 6.84 (3.27-14.3) 1.1 1.25 (0.17-9.09) 2.2 15.2 (3.16-73.3) 
Abbreviations: HR, hazard ratios 
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† Excluding and censoring anticoagulant use at baseline and follow up  
‡ The data in this row was also reported in Table 2 
The p-value for trend of the CHA2DS2-VASc score for ischemic stroke was <0.0001 for the 1, 5, and 10 year follow-up years 
 
 
Table 3.  Incidence rates per 1,000 person-years for ischemic stroke in participants without AF based on CHA2DS2-VASc risk score at 1 
year, 5 years, and 10 years of follow-up,
†
 Atherosclerosis Risk in Communities Study 
 CHA2DS2-VASc score 
 
0-1         2           3 4 ≥5  
No AF, Number of participants 4976 3282 1800 498 115 
1 Year of follow-up       
   # of Ischemic stroke events 4 13 5 6 4 
   Person-years 4959 3266 1790 489 114 
   Incidence rate (95% CI) 0.81 (0.27-1.92) 3.98 (2.23-6.61) 2.79 (1.06-6.12) 12.3 (5.10-25.3) 35.1 (11.7-83.4) 
5 Years of follow-up       
   # of Ischemic stroke events 29 57 38 15 6 
   Person-years 24407 15874 8660 2299 523 
   Incidence rate (95% CI) 1.19 (0.81-1.68) 3.59 (2.75-4.62) 4.39 (3.15-5.96) 6.52 (3.81-10.5) 11.5 (4.8-23.6) 
10 Years of follow-up       
   # of Ischemic stroke events 62 101 81 28 8 
   Person-years 47370 30351 16310 4151 897 
   Incidence rate (95% CI)‡ 1.31 (1.01-1.67) 3.33 (2.73-4.03) 4.97 (3.97-6.14) 6.75 (4.58-9.61) 8.9 (4.20-16.8) 
Abbreviations: AF, atrial fibrillation; CI, confidence interval.   
